Dr. Mitesh Borad, MD

Medical Oncology Scottsdale, AZ Male
NPI: 1801850573
Total Payments
$88,823
2024 Payments
$8,171
Companies
27
Transactions
113
Medicare Patients
7,369
Medicare Billing
$4.2M

Payment Breakdown by Category

Consulting$45,266 (51.0%)
Other$17,618 (19.8%)
Research$13,347 (15.0%)
Travel$8,212 (9.2%)
Food & Beverage$4,369 (4.9%)
Education$11.92 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $45,266 13 51.0%
Unspecified $13,347 12 15.0%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,647 7 14.2%
Travel and Lodging $8,212 21 9.2%
Food and Beverage $4,369 56 4.9%
Honoraria $3,000 1 3.4%
Compensation for serving as faculty or as a speaker for a medical education program $1,971 2 2.2%
Education $11.92 1 0.0%

Payments by Type

General
$75,476
101 transactions
Research
$13,347
12 transactions

Top Paying Companies

Company Total Records Latest Year
Jazz Pharmaceuticals Inc. $12,315 10 $0 (2023)
Incyte Corporation $11,876 12 $0 (2018)
Celgene Corporation $10,348 4 $0 (2018)
Merck Sharp & Dohme LLC $9,884 11 $0 (2023)
Exelixis Inc. $7,751 9 $0 (2022)
Halozyme Inc $5,361 14 $0 (2017)
ModernaTX, Inc. $4,898 2 $0 (2024)
AstraZeneca Pharmaceuticals LP $4,394 5 $0 (2023)
Genentech USA, Inc. $3,946 7 $0 (2022)
Boehringer Ingelheim Pharmaceuticals, Inc. $3,900 1 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $8,171 4 ModernaTX, Inc. ($4,898)
2023 $21,819 19 Jazz Pharmaceuticals Inc. ($12,315)
2022 $2,517 5 Exelixis Inc. ($1,980)
2021 $4,340 8 F. Hoffmann-La Roche AG ($2,006)
2020 $6,114 8 AstraZeneca Pharmaceuticals LP ($3,875)
2019 $10,563 23 Merck Sharp & Dohme Corporation ($7,139)
2018 $23,358 22 Incyte Corporation ($10,815)
2017 $11,941 24 Halozyme Inc ($5,361)

All Payment Transactions

113 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
11/07/2024 Ipsen Biopharmaceuticals, Inc Onivyde (Drug) Food and Beverage In-kind items and services $116.91 General
Category: Oncology
04/30/2024 ModernaTX, Inc. — Consulting Fee Cash or cash equivalent $4,800.00 General
01/19/2024 ModernaTX, Inc. — Food and Beverage In-kind items and services $98.30 General
01/16/2024 LES LABORATOIRES SERVIER Tibsovo (Drug) Consulting Fee Cash or cash equivalent $3,155.86 General
Category: Oncology
11/11/2023 AstraZeneca Pharmaceuticals LP — Food and Beverage In-kind items and services $37.21 General
11/10/2023 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Food and Beverage In-kind items and services $31.40 General
Category: Oncology
08/29/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Consulting Fee Cash or cash equivalent $10,500.00 General
08/29/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Travel and Lodging Cash or cash equivalent $109.25 General
08/11/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Food and Beverage In-kind items and services $73.65 General
08/11/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Food and Beverage In-kind items and services $47.84 General
08/11/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Food and Beverage In-kind items and services $23.91 General
08/11/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Food and Beverage In-kind items and services $17.51 General
08/10/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Travel and Lodging Cash or cash equivalent $864.19 General
08/10/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Travel and Lodging Cash or cash equivalent $350.09 General
08/10/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Food and Beverage In-kind items and services $182.50 General
06/05/2023 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $2,745.00 General
06/02/2023 Jazz Pharmaceuticals Inc. ZANIDATAMAB Food and Beverage In-kind items and services $145.62 General
03/09/2023 Eisai Inc. Lenvima (Drug) Consulting Fee Cash or cash equivalent $2,040.00 General
Category: Oncology
02/22/2023 Eisai Inc. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $638.80 General
Category: Oncology
02/22/2023 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $50.00 General
Category: Oncology
02/22/2023 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $50.00 General
Category: Oncology
02/22/2023 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $12.12 General
Category: Oncology
01/03/2023 Boehringer Ingelheim Pharmaceuticals, Inc. — Consulting Fee Cash or cash equivalent $3,900.00 General
09/10/2022 Genentech USA, Inc. TECENTRIQ (Biological) Food and Beverage In-kind items and services $89.64 General
Category: BioOncology
05/19/2022 Genentech USA, Inc. TECENTRIQ (Biological) Food and Beverage In-kind items and services $149.50 General
Category: BioOncology
123…5»

Research Studies & Clinical Trials

Study Name Company Amount Records
AX-CL-OTHER-PI-003908 - A phase II study of gemcitabine, cisplatin and Abraxane in advanced biliary cancers Celgene Corporation $6,699 1
CA040 Celgene Corporation $2,533 1
MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS F. Hoffmann-La Roche AG $2,006 1
NCI-2015-00578 Celgene Corporation $1,071 1
MS200647-047 EMD Serono, Inc. $1,012 7
TAS 120 Taiho Oncology, Inc. $26.43 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 44 1,666 41,059 $5.2M $977,871
2022 48 2,009 52,119 $5.9M $1.2M
2021 42 1,596 31,510 $3.2M $709,077
2020 54 2,098 56,102 $6.7M $1.3M
Total Patients
7,369
Total Services
180,790
Medicare Billing
$4.2M
Procedure Codes
188

All Medicare Procedures & Services

188 procedure records from CMS Medicare Utilization — Page 1 of 8

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
J9271 Injection, pembrolizumab, 1 mg Office 2023 27 7,604 $1.6M $327,704 19.9%
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj Office 2023 33 6,840 $1.4M $258,437 18.8%
J9299 Injection, nivolumab, 1 mg Office 2023 16 8,080 $968,683 $190,588 19.7%
J0897 Injection, denosumab, 1 mg Office 2023 20 2,040 $185,771 $37,708 20.3%
Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg Office 2023 15 1,405 $265,950 $32,491 12.2%
J9217 Leuprolide acetate (for depot suspension), 7.5 mg Office 2023 38 174 $66,027 $23,133 35.0%
96413 Administration of chemotherapy into vein, 1 hour or less Office 2023 193 226 $165,432 $22,462 13.6%
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg Office 2023 12 650 $89,999 $22,139 24.6%
Q5116 Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg Office 2023 11 556 $90,100 $10,705 11.9%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 86 163 $37,490 $10,600 28.3%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 78 84 $28,140 $6,663 23.7%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 29 29 $21,315 $4,911 23.0%
96375 Injection of additional new drug or substance into vein Office 2023 131 320 $39,360 $3,738 9.5%
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle Office 2023 43 60 $14,040 $3,337 23.8%
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l Office 2023 18 21 $17,850 $2,785 15.6%
96417 Administration of additional new drug or substance into vein, 1 hour or less Office 2023 48 57 $22,116 $2,756 12.5%
J9395 Injection, fulvestrant, 25 mg Office 2023 12 300 $10,492 $2,422 23.1%
96415 Administration of chemotherapy into vein, each additional hour Office 2023 56 97 $17,557 $2,097 11.9%
36591 Collection of blood sample from implanted device Office 2023 63 77 $9,625 $1,533 15.9%
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle Office 2023 51 55 $9,350 $1,424 15.2%
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less Office 2023 25 25 $8,000 $1,224 15.3%
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes Facility 2023 17 31 $6,045 $1,188 19.6%
96409 Administration of chemotherapy into vein using push technique Office 2023 12 14 $7,840 $1,079 13.8%
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less Office 2023 25 39 $6,045 $864.52 14.3%
96372 Injection of drug or substance under skin or into muscle Office 2023 60 70 $7,700 $761.61 9.9%
123…8»

About Dr. Mitesh Borad, MD

Dr. Mitesh Borad, MD is a Medical Oncology healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801850573.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitesh Borad, MD has received a total of $88,823 in payments from pharmaceutical and medical device companies, with $8,171 received in 2024. These payments were reported across 113 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($45,266).

As a Medicare-enrolled provider, Borad has provided services to 7,369 Medicare beneficiaries, totaling 180,790 services with total Medicare billing of $4.2M. Data is available for 4 years (2020–2023), covering 188 distinct procedure/service records.

Practice Information

  • Specialty Medical Oncology
  • Other Specialties Medical Oncology, Hematology & Oncology
  • Location Scottsdale, AZ
  • Active Since 04/12/2006
  • Last Updated 10/02/2020
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1801850573

Products in Payments

  • ZANIDATAMAB $12,315
  • Abraxane (Drug) $10,348
  • Cabometyx (Drug) $7,732
  • TECENTRIQ (Biological) $3,676
  • Tibsovo (Drug) $3,156
  • Lenvima (Drug) $2,791
  • Perjeta (Biological) $2,006
  • TIBSOVO (Drug) $1,971
  • KEYTRUDA (Biological) $1,489
  • Xermelo (Drug) $421.31
  • Avastin (Biological) $270.75
  • ONIVYDE (Drug) $121.10
  • Udenyca (Biological) $120.89
  • Onivyde (Drug) $116.91
  • Vectibix (Biological) $110.75
  • IMFINZI (Biological) $31.40
  • Zoladex (Drug) $17.61

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Scottsdale

Dr. Maciej Mrugala, Md Phd Mph, MD PHD MPH

Medical Oncology — Payments: $106,293

Medical Oncology $106,293

Dr. Erkut Borazanci, Md, Ms, MD, MS

Medical Oncology — Payments: $55,732

Medical Oncology $55,732

Rishi Agarwal, M.d, M.D

Medical Oncology — Payments: $13,710

Medical Oncology $13,710

Ashish Chintakuntlawar, Md, Phd, MD, PHD

Medical Oncology — Payments: $1,500

Medical Oncology $1,500

John Bibb, Md, MD

Medical Oncology — Payments: $1,423

Medical Oncology $1,423

Dr. Lisa Sproat, Md, Msw, MD, MSW

Medical Oncology — Payments: $517.25

Medical Oncology $517.25